Crown Bioscience’s Robust FACS Platform

invitro-magnifyglass.png

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Crown Bioscience’s FACS services deliver the answers researchers need to understand functional changes and immunophenotypic patterns induced by tumors, individual specimen variations, and investigational compounds.

CrownBio’s FACS services are holistically optimized for cancer research. From sample preparation to data delivery, our in house experts ensure that oncology drug developers can make confident conclusions about their compound.

CrownBio’s FACS Platform Advantages

  • Experience working with tumor samples
    • >20 optimized protocols for tumor tissue dissociation
    • Parent gating strategies to overcome tumor complexity

  • Quality of data
    • Central data processing and analysis
    • Use of controls to ensure accurate staining, processing, and gating

  • Throughput capability
    • Multicolor flow assays (up to 17 colors)
    • 96-well plate attachment to allow for high-throughput screening (HTS)

  • Expertise
    • Dedicated team of FACS experts to help determine dissociation protocols, generate panel configurations, suggest gating strategies, etc.

  • Data reports
    • Dynamic and informative reporting packages that can include raw data, statistical analyses, observations, recommendations, data visualization, etc.
    • Convenient cloud portal

Contact us today for advice on advancing your compounds with CrownBio’s FACS Platform.

Quick Facts

Posters

  • AACR 2015 1038 - Cell-based Screening Identifes Gene Expression Signature Correlated with Sensitivity to PI3KmTOR Dual Inhibitor BEZ235
  • AACR 2014 3440 - Cell-based Screening Identifies Gene Expression Signature Correlated with Sensitivity to MEK Inhibitor Trametinib

Related Services

Blog Posts